United Therapeutics (UTHR) General Counsel A Sells $4.1M of Stock

United Therapeutics Corporation EVP & General Counsel Paul A. Mahon sold 8,300 shares of company stock on September 17, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the shares were disposed of at an average price of $497.54 for a total value of roughly $4.13 million.

UTHR United Therapeutics Corporation

$540.28 ▲ +8.77% year to date

1M 3M YTD

Daily close · Oct 19, 2026

Inside Paul A. Mahon's United Therapeutics Trade

The sale covered 8,300 shares at $497.54 each, totaling about $4.13 million. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. On the day of the transaction, United Therapeutics stock closed at $497.27.

Other Institutional Activity in United Therapeutics

Avoro Capital Advisors LLC grew its holdings by 147,804 shares, ending with 2,777,777 shares worth about $1.51 billion. Renaissance Technologies LLC reduced its stake by 78,271 shares, finishing with 1,708,739 shares valued at roughly $928.1 million. Jupiter Topco LLC increased its position by 415,564 shares, representing a 100.0% change to end with 831,129 shares worth about $451.4 million.

United Therapeutics Corporation Stock Up 1.7%

United Therapeutics shares recently traded around $541.98 as of October 16, 2026, which is up about 9.0% from the event close of $497.27 on September 17, 2026. The stock trades above its 50-day moving average of $514.75 and above its 200-day moving average of $527.28.

Recent Earnings

United Therapeutics reported trailing twelve-month revenue of $3.15 billion and earnings of $27.89 per share. The company posts a net profit margin of 41.6% and a return on equity of 19.3%. The next earnings report is scheduled for October 28, 2026.

Dividend

United Therapeutics currently does not pay a dividend, maintaining a dividend payout ratio of 0.0% and a dividend yield of 0.0%.

Insider Buying and Selling at United Therapeutics Corporation

Chairperson and CEO Martine A. Rothblatt sold 9,500 shares on September 17, 2026, at an average price of $496.06 for a total of $4.71 million under a pre-arranged plan. Later, on October 9, 2026, Rothblatt sold another 9,500 shares at $544.94 per share totaling $5.18 million. On October 12, 2026, Rothblatt sold a further 9,500 shares at $550.70 for $5.23 million. Additionally, Paul A. Mahon sold 8,300 shares on October 15, 2026, at an average price of $544.30 for a total value of $4.52 million.

Analysts Set New Price Targets

On July 10, 2026, B of A Securities maintained its Neutral rating while lowering its price target to $613.00 from $620.00. JP Morgan maintained an Overweight rating on July 23, 2026, raising its price target to $687.00 from $685.00. RBC Capital maintained an Outperform rating on August 6, 2026, adjusting its price target to $677.00 from $704.00. Goldman Sachs initiated coverage with a Sell rating and a $321.00 price target on September 24, 2026. BTIG upgraded the stock to Buy with a $728.00 price target on October 1, 2026. The stock carries a consensus buy recommendation with a mean price target of $656.93 across 14 analyst opinions.

About United Therapeutics

United Therapeutics Corporation focuses on creating and selling treatments for patients dealing with severe and chronic medical conditions. Operating in the healthcare sector as a specialty drug maker, the company works on advancing medical options from its headquarters in Silver Spring, Maryland.

Bottom Line

Investors will look toward the upcoming earnings release on October 28, 2026, for further financial updates. Insider transactions and institutional filing updates will continue to offer insight into stakeholder positioning.